Tumor-associated carbohydrate antigens (TACAs) are key components of cancer vaccines. A variety of “native” TACA-based vaccines have shown immunogenicity and protection in pre-clinical animal studies, however the weak immunogenicity, in vivo instability and poor bioavailability, have discouraged their further evaluations in clinical studies. We report on a new “improved” vaccine prototype 8 composed by four clustered Tn-antigen mimetics and a T-helper cell peptide epitope that are conjugated to a cyclopeptide carrier. Immunization of mice with vaccine 8 (i) was safe, (ii) induced a strong and long-lasting Tn-specific IgM/IgG antibodies able to recognize “native” carbohydrate antigens; (iii) produced high titres of IgG1, IgG2a and IgG3 antibodies; (iv) raised a significant antibody-dependent regression of tumors and protection. All together, these findings pave the way for a clinical development of vaccine 8 as a safe and effective therapeutic vaccine against Tn-expressing cancers.